Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1M | 8M |
| Gross Profit | 0 | 0 | 0 | 900K | 7M |
| Operating Income | -28M | -32M | -38M | -42M | -25M |
| EBITDA | -28M | 632K | 529K | -31M | -18M |
| Net Income | -27M | -31M | -37M | -41M | -21M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$8.05
+3.74% today
Window Change
-13.53%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SELLAS Life Sciences Group, Inc. (SLS) is a Healthcare stock with a market cap of $700.00M and listed on NASDAQ. The stock last traded around $8.05 and down 13.5% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +50.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +50.0%, free cash flow +19.8% with operating margin 0.0% and ROIC -39.3%. Stock Foundry combines SLS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SLS Max Drawdown
-23.20%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SLS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$7.6M
+660.0% YoY
FY Net Income
-$20.7M
+49.9% YoY
Free Cash Flow
-$26.0M
+8.1% YoY
Revenue Growth
+0.0%
EPS Growth
+50.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1M | 8M |
| Gross Profit | 0 | 0 | 0 | 900K | 7M |
| Operating Income | -28M | -32M | -38M | -42M | -25M |
| EBITDA | -28M | 632K | 529K | -31M | -18M |
| Net Income | -27M | -31M | -37M | -41M | -21M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 72M | 14M | 3M | 17M | 21M |
| Total Assets | 78M | 19M | 6M | 21M | 26M |
| Total Liabilities | 7M | 10M | 14M | 16M | 6M |
| Shareholder Equity | 71M | 9M | -8M | 5M | 20M |
| Total Debt | 1M | 1M | 906K | 945K | 808K |
| Net Debt | -71M | -13M | -2M | -16M | -21M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
26M
-9.3% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
26M
+8.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-63.1%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.